Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Flow injection analysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    195 result(s) found for: Flow injection analysis. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002266-40 Sponsor Protocol Number: CAIN457ADE02 Start Date*: 2013-12-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 ...
    Medical condition: active chronic plaque-type psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002187-26 Sponsor Protocol Number: neostigmine2019 Start Date*: 2019-08-28
    Sponsor Name:KU Leuven - TARGID
    Full Title: A Prospective evaluation of the effect of a single dose of neostigmine in patients with patients with weak or absent esophageal peristalsis
    Medical condition: Patients with complaints of dysphagia and poor esophageal motility
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005685-30 Sponsor Protocol Number: 2015-005685-30 Start Date*: 2016-04-08
    Sponsor Name:Hôpital Erasme
    Full Title: Evaluation of microcirculation alterations in cardiac surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and biological analysis
    Medical condition: Cardiac pathology eligible for surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001498-63 Sponsor Protocol Number: BIO101-CL05 Start Date*: 2020-07-22
    Sponsor Name:Biophytis S.A.
    Full Title: Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...
    Medical condition: Confirmed infection with SARS-CoV-2 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047465 Viral infections NEC HLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019017-25 Sponsor Protocol Number: CSOM230CIC01T Start Date*: Information not available in EudraCT
    Sponsor Name:Freistaat Bayern, represented by Universität Regensburg
    Full Title: Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size
    Medical condition: Primary inoperable thymoma and/or local recurrent thymoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000500-26 Sponsor Protocol Number: 01-1-101 Start Date*: Information not available in EudraCT
    Sponsor Name:Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd)
    Full Title: An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases
    Medical condition: Regadenoson will be used as a pharmacologic stress agent in paediatric patients with cardiovascular problems, undergoing a clinically indicated myocardial perfusion MRI
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10065141 Vascular diagnostic procedure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005066-30 Sponsor Protocol Number: RG_14-088 Start Date*: 2018-03-20
    Sponsor Name:The University of Birmingham
    Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005075-91 Sponsor Protocol Number: STRATIFY-1 Start Date*: 2018-08-30
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: LOW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM
    Medical condition: Acute Pulmonary Embolism, intermediate high risk (visible impact on right ventricular structure and function, and biochemical markers og myocardial damage according to the European Society of Cardi...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001177-78 Sponsor Protocol Number: APHP191008 Start Date*: 2021-02-25
    Sponsor Name:University of Utah
    Full Title: Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE
    Medical condition: Pregnant women with Antiphospholipid Syndrom (APS) and Lupus Antocoagulant (LAC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    20.1 100000004848 10058347 Lupus anticoagulant positive LLT
    20.0 100000004848 10058355 Lupus anticoagulant LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001515-22 Sponsor Protocol Number: S54226 Start Date*: 2012-05-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: Cytomegalovirus infection and the influenza vaccination response in older persons
    Medical condition: Humoral and cellular immune response after vaccination in older people
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001582-33 Sponsor Protocol Number: Er-01-Perf-Stroke Start Date*: 2012-09-19
    Sponsor Name:University Hospital Erlangen
    Full Title: Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease
    Medical condition: Patients with high grade carotid artery stenosis or acute cerebral ischemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001827-76 Sponsor Protocol Number: 1983 Start Date*: 2009-11-26
    Sponsor Name:Erasmusm MC, Rotterdam, The Netherlands
    Full Title: The role of TSH in the human immune system, a clinical trial
    Medical condition: All conditions in which a T cell immunodeficiency is present. Examples are genetic immunodeficiencies, chronic viral infections like HIV, after chemotherapy or bone marrow transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021463 Immunodeficiency with predominant T-cell defect, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006126-10 Sponsor Protocol Number: Efalizumab in CTCL Start Date*: 2008-11-27
    Sponsor Name:Charité - University Hospital Berlin
    Full Title: pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma
    Medical condition: The cutaneous T-cell lymphoma (also known as Sézary syndrome) is a common disorder of proliferated cells with characteristics of maligne t-lymphocytes immigrating from the cutaneous blood vessels t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024485-21 Sponsor Protocol Number: daisy Start Date*: 2013-04-15
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY
    Medical condition: Patients with a single ≥ 50% e <75% coronary stenosis (visually extimated) at angiography, in one ore more coronary vessels).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001583-29 Sponsor Protocol Number: Er-02-Perf-AD Start Date*: 2012-10-18
    Sponsor Name:University Hospital Erlangen
    Full Title: Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and ...
    Medical condition: Patients with dementing disorders, namely minor alzheimers disease or subjects with mild cognitive impairment and normal controls
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003854-99 Sponsor Protocol Number: CLL17 Start Date*: 2021-06-11
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patie...
    Medical condition: Patients with previously untreated CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024265-40 Sponsor Protocol Number: KETA-FAN Start Date*: 2011-10-27
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain
    Medical condition: Phantom limb pain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034804 Phantom limb pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005254-24 Sponsor Protocol Number: HA009 Start Date*: 2008-01-14
    Sponsor Name:Nuvelo, Inc
    Full Title: PHASE 2, MULTICENTER, OPEN-LABEL, TWO-STAGE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRA-ARTERIAL CATHETER-DIRECTED ALFIMEPRASE FOR RESTORATION OF NEUROLOGIC FUNCTION AND RAPID OPENING OF ART...
    Medical condition: Acute Ischemic Stroke (AIS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003197-26 Sponsor Protocol Number: IOM-120 Start Date*: 2008-05-29
    Sponsor Name:BRACCO IMAGING
    Full Title: Studio randomizzato di fase IV, doppio cieco, multicentrico, per il confronto di Iomeron 400 con Visipaque 320 nell'angiografia coronarica con Tomografia Computerizzata a doppio tubo (DS-CTA)
    Medical condition: CAD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:38:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA